Sunday 11 October 2026
Export all NVO data to Excel Powerpack
Novo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024. In the quarter to June 2026, revenue grew 4.47%, EPS fell 18.7%, free cash flow grew 71.6% and total debt rose 44.4%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for five.
38.64
0.46
+1.20%
Follow NVO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
68.91% | 61.81% | 74.07% | 60.84% | |
Piotroski F-Score |
4 | 5 | 5 | 5 | |
| 22.03% | 20.71% | 24.29% | 22.00% | ||
ROIC |
33.99% | 27.38% | 28.59% | 28.67% | |
Return on Tangible Assets |
69.35% | 62.02% | 70.54% | 58.25% | |
Average Days of Receivables |
113.04 | 105.33 | 112.52 | 119.76 | |
Free Cash Flow per Share |
2.12 | 0.99 | 1.10 | 1.72 | |
Free Cash Flow |
9,416.60 | 4,388.93 | 4,863.47 | 7,610.53 | |
Capital Expenditures |
(9,564.48) | (13,643.11) | (13,470.33) | (12,814.25) | |
| Other line items | |||||
Cash ROIC |
19.20% | 8.08% | 8.28% | 11.92% | |
Accounts Receivable Turnover |
3.57 | 3.58 | 3.65 | 3.44 | |
Accounts Payable Turnover |
2.31 | 2.48 | 3.63 | 3.02 | |
Inventory Turnover |
1.30 | 1.32 | 1.31 | 1.33 | |
Average Days of Payables |
161.91 | 122.67 | 91.86 | 83.55 | |
Days of Inventory on Hand |
321.75 | 308.10 | 318.66 | 294.06 | |
Tax Rate |
(0.21) | (0.22) | (0.22) | (0.22) | |
Research and Development Expense of Revenue |
16.33% | 16.84% | 15.77% | 17.54% | |
Selling, General and Administrative Expense of Revenue |
23.22% | 22.74% | 20.49% | 19.64% | |
Share Based Compensation of Revenue |
0.00% | 1.96% | 0.00% | 0.00% | |
Interest Coverage |
11.73 | 18.83 | 27.52 | 69.27 | |
Operating CF/Net income |
1.24 | 1.16 | 0.96 | 1.12 | |
Depreciation/Fixed assets |
0.11 | 0.11 | 0.10 | 0.12 | |
Capex/Depreciation |
(2.91) | (4.10) | (4.03) | (3.08) | |
Revenue per Share |
10.51 | 10.53 | 11.47 | 11.60 | |
Operating CF per Share |
4.27 | 4.06 | 4.13 | 4.60 | |
Capex per Share |
(2.15) | (3.07) | (3.03) | (2.89) | |
Capex to Sales |
0.20 | 0.29 | 0.26 | 0.25 |
Columns are period end dates